MarketerTakeda Pharmaceutical Company Ltd.

ADYNOVATE® (Antihemophilic Factor (Recombinant), PEGylated) is a recombinant full-length PEGylated human coagulation Factor VIII for the treatment of Hemophilia A. Nektar’s PEGylation technology, originally licensed to Baxter (now Takeda), allows ADYNOVATE to extend its half-life vs. Advate®, with improved dosing. The product was approved in the U.S. in November 2015.

Background

HCRx purchased the royalty interests on worldwide net sales of ADYNOVATE and MOVANTIK from Nektar Therapeutics. Nektar monetized these non-strategic royalty interests in order to further fund development of its strategic pipeline.

Note: This transaction also appears in the Corporate Financing section under NEKTAR.